Paradeep Phosphates Introduces 'PSOP 2026' Stock Option Plan
Paradeep Phosphates Limited has formulated the 'PSOP 2026' stock option plan, approved by the Board on July 28, 2026. It allows options for up to 20 lakh equity shares of ₹10 face value, subject to shareholder approval. Vesting occurs after a minimum of one year, with a two-year exercise period.
The introduction of a stock option plan can impact future equity dilution and employee motivation, making it a medium-term impact event.
The announcement is about the formulation of a stock option plan, which is a standard corporate action for employee incentives. It does not immediately impact financials but is subject to shareholder approval.
Paradeep Phosphates Limited (PARADEEP) announced the formulation of the ‘Paradeep Phosphates Limited Performance Stock Option Plan 2026’ (PSOP 2026). This plan was considered and approved by the Board of Directors at their meeting held on July 28, 2026, based on the recommendation of the Nomination and Remuneration Committee.
The introduction of PSOP 2026 is subject to the approval of the shareholders. The plan allows for the grant of stock options exercisable into a maximum of 20,00,000 (Twenty Lakhs) Equity Shares, each with a face value of ₹10. The exercise price will be the face value of the equity shares on the date of grant, or as decided by the Committee, not lower than the face value.
The scheme is in compliance with SEBI (Share Based Employee Benefits) Regulations, 2021. Eligibility for the plan will be determined by the Committee based on roles with high impact and contribution to organizational growth. There will be a minimum vesting period of one year between grant and vesting, with a maximum vesting period extending up to three years, potentially in tranches. The exercise period for vested options will not exceed two years from the respective vesting date. The PSOP 2026 will be administered by the Committee authorized by the Board.
What to do with a filing like this
Paradeep Phosphates Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Paradeep Phosphates Limited. Read the original for the full detail.